The Clinical Efficacy of Ginkgo biloba Leaf Preparation on Ischemic Stroke: A Systematic Review and Meta-Analysis

Table 1

Details from trials.

First author, year	Reference no.	Intervention		Sample size		Age		Duration	Outcome
		Treatment	Control	Treatment	Control	Treatment	Control
Sun T, 2012	[14]	Aspirin + ozagrel + Ginkgo dameer	Aspirin + ozagrel	40	40	66.5	64.8	2 weeks	a, b
Zhou YF, 2016	[15]	Routine + shuxuening	Routine	63	63	68.3 ± 8.5	67.1 ± 7.9	2 weeks	a, b, c
Shi YF, 2017	[16]	Routine + aspirin + ginkgo ester dispersive tablets	Routine + aspirin	41	41	69.42 ± 7.24	68.72 ± 8.14	2 weeks	d, e
Wang LM, 2017	[17]	Edaravone + propranolol + aspirin + mannitol + furosemide + Ginkgo biloba leaf extract	Edaravone + propranolol + aspirin + mannitol + furosemide	73	73	59.48 ± 13.24	58.91 ± 13.07	4 weeks	d, f
Yang T, 2017	[18]	Routine + alprostadil + ginkgo ester dispersive tablets	Routine + alprostadil	49	49	68.9 + 1.7	68.2 ± 1.6	2 weeks	d, f
Zhou G, 2018	[19]	Routine + rosiglitazone + ginkgo ester dispersive tablets	Routine + rosiglitazone	51	51	53.64 ± 10.25	53.72 ± 10.38	4 weeks	a, b, d, e
Zhou QW, 2019	[20]	Rt-PA + ginkgolide injection	Rt-PA	44	43	63.08 ± 7.18	62.97 ± 7.25	2 weeks	a, b
Chen E, 2020	[21]	Mannitol + aspirin + mecobalamin + ginkgo ester dropping pills	Mannitol + aspirin + mecobalamin	50	50	53.10 ± 10.39	52.39 ± 10.23	2 weeks	d, e
Xiao H, 2020	[22]	Butylphthalide + ginkgo diterpene lactone glutamine	Butylphthalide	41	41	62.15 ± 6.45	61.37 ± 6.44	2 weeks	a, b
Wu Y, 2020	[23]	Routine + ginkgolide injection	Routine treatment	46	46	68.9 + 1.7	68.2 ± 1.6	2 weeks	d, f
Zhang DN, 2020	[24]	Routine + butylphthalide + ginkgolide injection	Routine + butylphthalide	39	39	61.98 ± 7.65	61.82 ± 7.51	4 weeks	a, b, c, f
Shi XJ, 2021	[25]	Routine + Butylphthalide injection + diterpene lactone Ginkgo biloba injection	Routine + Butylphthalide injection	63	63	65.13 ± 7.29	64.23 ± 6.18	2 weeks	b, c, d,
Zhang TT, 2021	[26]	Rt-PA + Ginkgo biloba extract injection	Rt-PA	30	30	56.28 ± 5.09	56.91 ± 5.38	1 week	a, b, c, e, f

Outcomes: (a) NIHSS; (b) clinical therapeutic effect; (c) BI; (d) plasma viscosity; (e) fibrinogen; (f) adverse reactions.